SCHEMBL3590205

SCHEMBL3590205

CCOC(=O)c1c2c(n(C)c1-c1ccccc1C)-c1cc[n+](Cc3ccccc3)cc1CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HPGD P15428 1/20 0.38
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
PLCG1 P19174 1/20 0.37
PAX8 Q06710 1/20 0.37
GAA P10253 2/20 0.36
POLB P06746 2/20 0.36
PTGES O14684 1/20 0.35
ALOX5 P09917 1/20 0.35
PDE4D Q08499 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HIF1A Q16665 2/20 0.35
LMNA P02545 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588774 0.91 KDM4E (0.33) ALDH1A1KDM4EL3MBTL1
SCHEMBL3597814 0.89 NPSR1 (0.38) ALDH1A1SMN1; SMN2KDM4EL3MBTL1HPGD
SCHEMBL3603849 0.88 MAPT (0.41) MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL3609436 0.82 ALOX5 (0.44) MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL3597842 0.79 CDK4 (0.39) MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL17381182 0.68 CYP19A1 (0.40) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL3598214 0.64 SIRT3 (0.37)
SCHEMBL10314667 0.64 TSHR (0.47) MAPTALDH1A1SMN1; SMN2L3MBTL1KMT2A
Bromide SCHEMBL7962605 0.64 SMN1; SMN2 (0.56) MAPTALDH1A1SMN1; SMN2KDM4EGAA
SCHEMBL11066786 0.64 ALDH1A1 (0.45) MAPTALDH1A1SMN1; SMN2KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118102-B1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-8207180-B2 Tricyclic indoles and (4,5-dihydro) indoles NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-26 US disclosed
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-25 US disclosed
EP-2118102-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES Nerviano Medical Sciences S.r.l. (IT) 2009-11-18 EP disclosed
WO-2008065054-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES CDC7, CDK7, CDK17 MAPT 2291/4885ALDH1A1 2469/4885SMN1; SMN2 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.